New NCCN Guidelines published for Vulvar Cancer

NewsGuard 100/100 Score

It is estimated that more than 5,000 cases of Vulvar Cancer were diagnosed in the United States in 2015, and approximately 1,000 women died from the disease. In order to provide comprehensive, up-to-date clinical treatment guidelines for this rare cancer, the National Comprehensive Cancer Network® (NCCN®), an alliance of 26 of the nation's leading cancer centers, has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Vulvar Cancer. The new NCCN Guidelines® for Vulvar Cancer provide recommendations on the evaluation and treatment of squamous cell carcinoma of the vulva and include principles of surgery, principles of radiation therapy, and systemic therapy.

NCCN Guidelines document evidence-based consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.

"The creation of these new guidelines represents a multidisciplinary effort to codify appropriate standards of care for patients with vulvar cancer, based on available published evidence and contemporary patterns of practice," said Wui-Jin Koh, MD, Professor of Radiation Oncology, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, and Co-Chair, NCCN Guidelines Panel for Vulvar Cancer.

"These guidelines are essential to establish a standard of care for this rare disease, and serve as a platform for future investigations and improved outcomes," said Benjamin E. Greer, MD, Director of Gynecological Cancer, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, and Co-Chair, NCCN Guidelines Panel for Vulvar Cancer.

With the publication of the NCCN Guidelines for Vulvar Cancer, the library of NCCN Guidelines now includes 62 clinical guidelines detailing sequential management decisions and interventions that currently apply to 97 percent of cancers affecting people in the United States, as well as cancer prevention, detection and risk reduction, and age-related recommendations.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer